Argenx

New trial design addresses FDA concerns.

FDA may still have concerns.

Natural transition.

Unexpected timing.

Phase 2 showed strong efficacy.

Heterogeneous population.

MGII is validated in literature (Neurology 2016), correlates with MG-ADL (r=0.91), lower floor effect better for mild patients. FDA interactions suggest alignment. Vyvgart already approved in gMG reduces regulatory risk.

No precedent for MGII as primary endpoint. FDA could require additional data or different endpoint. Novel endpoint = regulatory uncertainty.

Post-hoc ADAPT data showed stat sig treatment differences as early as weeks 1-2, with clear separation at Week 4. IgG reduction happens rapidly with FcRn inhibition.

4 weeks is short. KOL would prefer 12 weeks. Placebo variability risk. May not capture full treatment effect.

Same pathophysiology (AChR antibodies), same muscle groups (diplopia, ptosis). 50-70% conversion rate suggests oMG is essentially early-stage gMG.

ADAPT excluded pure oMG (MGFA Class I). Different severity, different AChR+ rates (40-77% vs 85-90%). May not translate.

80% based on: 1) Overlapping pathophysiology; 2) Positive post-hoc data at Week 4; 3) Case reports showing efficacy; 4) KOL validation of MGII; 5) FcRn class de-risked by Rystiggo data; 6) Low historical placebo response.

Novel endpoint never approved. Short duration. Different population (MGFA Class I). Seronegative inclusion adds risk. Two failures in a row would hurt sentiment.

In gMG, Vyvgart faces real competition — J&J Imaavy (approved Apr 2025, broadest label), UCB Rystiggo (approved), Immunovant IMVT-1402 (coming). In CIDP, Vyvgart is completely alone — and that monopoly may last through 2029+. UCB tried CIDP with Rystiggo and failed (Phase 3 discontinued 2023). J&J has no active CIDP program for nipocalimab. Immunovant showed Phase 2b CIDP data for batoclimab but pivoted to IMVT-1402 (no CIDP data until 2028+). Penetration is only ~20% — ~2,500 of 12,000+ inadequately controlled US patients on Vyvgart for CIDP. The prefilled syringe is accelerating new starts. CIDP is chronic and lifelong — every new patient is an annuity. CIDP alone could be a $3-4B franchise with monopoly economics (no price concessions, no rebate wars, no formulary battles).

CIDP is a niche market — the inadequately controlled population may be smaller than estimated. Some patients stabilize on IVIg and never switch. The annual cost of Vyvgart creates payer pushback that limits penetration. Even in a monopoly, there is a ceiling. New entrants (complement inhibitors, other mechanisms) could eventually challenge from a different angle.

CIDP approval validated the platform expansion thesis beyond gMG. Seronegative gMG data was positive (Aug 2025). The FcRn mechanism has strong biological rationale across IgG-mediated diseases. argenx has world-class trial execution — the team that delivered ADAPT and ADHERE is running these trials. Even 3 out of 5 successes would be a strong outcome.

The pemphigus failure (ADDRESS Phase 3, Dec 2023 — 35.5% vs 30.3% placebo, not significant) proved FcRn does not automatically translate across IgG-mediated diseases. ITP had mixed earlier results (ADVANCE-3/4 not clean enough for filing — hence ADVANCE-NEXT). TED is unvalidated for FcRn — no FcRn inhibitor has Phase 3 TED data yet. Myositis (ALKIVIA) tests three heterogeneous subtypes that may respond differently. At $51B market cap / ~9x FY2026 revenue / ~32x forward P/E, the stock is priced for the platform thesis to largely work. If TED and myositis both fail in H2 2026, you lose $2-4B of peak sales from SOTP AND the FcRn-works-everywhere narrative cracks for the second time. Re-rates from proven platform to MG+CIDP company at $4-5B peak.

BAFF/APRIL face significant challenges: (1) Broad immune suppression by killing B cells AND plasma cells may cause serious infections and hypogammaglobulinemia. (2) Telitacicept has a mixed safety record in lupus. (3) MG-specific data is very early — years away from registration. (4) Even if they work, not all patients will achieve remission — Vyvgart remains necessary for ongoing management. (5) Combination therapy (Vyvgart + BAFF/APRIL) could EXPAND the market by offering induction (Vyvgart) + remission-seeking (BAFF/APRIL) paradigm. (6) argenx could in-license or acquire a BAFF/APRIL asset to protect its franchise.

If BAFF/APRIL inhibitors demonstrate treatment-free remission in MG, Vyvgart's long-term revenue model (chronic dosing, $80-100K/year/patient indefinitely) would be fundamentally challenged. The threat is not about better short-term efficacy — it's about rendering chronic IgG lowering unnecessary if the underlying disease can be "cured" at the B-cell/plasma cell level. This is a thesis-level threat that few on the Street are discussing. Timeline: likely 3-5+ years away, but these molecules are advancing rapidly.

Vyvgart has a 4+ year head start in CIDP with proven Phase 3 data (ADHERE). C1s inhibitors are 3+ years from approval (CAPTIVATE primary completion Dec 2028, Sanofi MOBILIZE/VITALIZE mid-2027). Vyvgart will have deeply entrenched prescriber relationships and patient base by then. Even if complement inhibitors work, the CIDP market may be additive (complement-driven subset + antibody-driven subset = larger total market). Weekly SubQ self-injection is already established as convenient.

CIDP is heterogeneous. Case series show some patients DETERIORATE when switching from IVIg to Vyvgart (4 patients relapsed within 2-9 days). This suggests complement-mediated mechanisms are operative in patients where FcRn inhibition alone is insufficient. IVIg works through multiple mechanisms including anti-complement — a complement inhibitor may capture more of IVIg therapeutic benefit than FcRn alone. Claseprubart offers Q2W dosing (half the frequency of Vyvgart), and riliprubart has Phase 2 CIDP data (88% SOC-treated improved/stable). If complement inhibitors prove broadly effective across CIDP subtypes, they could be positioned as mechanistically more appropriate than FcRn inhibition. Sanofi VITALIZE trial directly compares riliprubart to IVIg — if it shows superiority, it reframes the treatment algorithm.